Lichen  ||| S:0 E:7 ||| JJ
planus  ||| S:7 E:14 ||| JJ
secondary  ||| S:14 E:24 ||| JJ
complications  ||| S:24 E:38 ||| NNS
associated  ||| S:38 E:49 ||| VBN
with  ||| S:49 E:54 ||| IN
the  ||| S:54 E:58 ||| DT
use  ||| S:58 E:62 ||| NN
of  ||| S:62 E:65 ||| IN
biologic  ||| S:65 E:74 ||| JJ
therapy  ||| S:74 E:82 ||| NN
for  ||| S:82 E:86 ||| IN
rheumatoid  ||| S:86 E:97 ||| FW
arthritis  ||| S:97 E:107 ||| FW
Biologic  ||| S:107 E:116 ||| FW
therapy  ||| S:116 E:124 ||| FW
such  ||| S:124 E:129 ||| JJ
as  ||| S:129 E:132 ||| IN
Etanercept ||| S:132 E:142 ||| NNP
,  ||| S:142 E:144 ||| ,
which  ||| S:144 E:150 ||| WDT
is  ||| S:150 E:153 ||| VBZ
a  ||| S:153 E:155 ||| DT
tumor  ||| S:155 E:161 ||| NN
necrosis  ||| S:161 E:170 ||| NN
factor  ||| S:170 E:177 ||| NN
alpha  ||| S:177 E:183 ||| NNS
( ||| S:183 E:184 ||| -LRB-
TNF-Î± ||| S:184 E:189 ||| NNP
)  ||| S:189 E:191 ||| -RRB-
inhibitor ||| S:191 E:200 ||| NN
,  ||| S:200 E:202 ||| ,
has  ||| S:202 E:206 ||| VBZ
been  ||| S:206 E:211 ||| VBN
extensively  ||| S:211 E:223 ||| RB
used  ||| S:223 E:228 ||| VBN
as  ||| S:228 E:231 ||| IN
election  ||| S:231 E:240 ||| NN
therapy  ||| S:240 E:248 ||| NN
in  ||| S:248 E:251 ||| IN
rheumatoid  ||| S:251 E:262 ||| JJ
arthritis ||| S:262 E:271 ||| NN
.  ||| S:271 E:273 ||| .
The  ||| S:273 E:277 ||| DT
purpose  ||| S:277 E:285 ||| NN
of  ||| S:285 E:288 ||| IN
this  ||| S:288 E:293 ||| DT
case  ||| S:293 E:298 ||| NN
presentation  ||| S:298 E:311 ||| NN
was  ||| S:311 E:315 ||| VBD
to  ||| S:315 E:318 ||| TO
inform  ||| S:318 E:325 ||| VB
about  ||| S:325 E:331 ||| IN
the  ||| S:331 E:335 ||| DT
possibility  ||| S:335 E:347 ||| NN
that  ||| S:347 E:352 ||| IN
lichen  ||| S:352 E:359 ||| JJ
planus  ||| S:359 E:366 ||| JJ
lesions  ||| S:366 E:374 ||| NNS
could  ||| S:374 E:380 ||| MD
potentially  ||| S:380 E:392 ||| RB
become  ||| S:392 E:399 ||| VB
complicated  ||| S:399 E:411 ||| VBN
by  ||| S:411 E:414 ||| IN
secondary  ||| S:414 E:424 ||| JJ
infections  ||| S:424 E:435 ||| NNS
in  ||| S:435 E:438 ||| IN
patients  ||| S:438 E:447 ||| NNS
treated  ||| S:447 E:455 ||| VBN
with  ||| S:455 E:460 ||| IN
Etanercept ||| S:460 E:470 ||| NNP
.  ||| S:470 E:472 ||| .
Furthermore ||| S:472 E:483 ||| RB
,  ||| S:483 E:485 ||| ,
we  ||| S:485 E:488 ||| PRP
aimed  ||| S:488 E:494 ||| VBD
at  ||| S:494 E:497 ||| IN
analyzing  ||| S:497 E:507 ||| VBG
if  ||| S:507 E:510 ||| IN
the  ||| S:510 E:514 ||| DT
complication  ||| S:514 E:527 ||| NN
of  ||| S:527 E:530 ||| IN
the  ||| S:530 E:534 ||| DT
cutaneous  ||| S:534 E:544 ||| JJ
lesion  ||| S:544 E:551 ||| NN
was  ||| S:551 E:555 ||| VBD
coincidental  ||| S:555 E:568 ||| JJ
or  ||| S:568 E:571 ||| CC
it  ||| S:571 E:574 ||| PRP
was  ||| S:574 E:578 ||| VBD
due  ||| S:578 E:582 ||| JJ
to  ||| S:582 E:585 ||| TO
the  ||| S:585 E:589 ||| DT
immunosuppressive  ||| S:589 E:607 ||| JJ
systemic  ||| S:607 E:616 ||| JJ
therapy ||| S:616 E:623 ||| NN
,  ||| S:623 E:625 ||| ,
and  ||| S:625 E:629 ||| CC
whether  ||| S:629 E:637 ||| IN
the  ||| S:637 E:641 ||| DT
infected  ||| S:641 E:650 ||| JJ
lesion  ||| S:650 E:657 ||| NN
would  ||| S:657 E:663 ||| MD
respond  ||| S:663 E:671 ||| VB
to  ||| S:671 E:674 ||| TO
antibiotic  ||| S:674 E:685 ||| JJ
therapy ||| S:685 E:692 ||| NN
.  ||| S:692 E:694 ||| .
The  ||| S:694 E:698 ||| DT
patient  ||| S:698 E:706 ||| NN
was  ||| S:706 E:710 ||| VBD
a  ||| S:710 E:712 ||| DT
59-year-old  ||| S:712 E:724 ||| JJ
woman  ||| S:724 E:730 ||| NN
with  ||| S:730 E:735 ||| IN
rheumatoid  ||| S:735 E:746 ||| JJ
arthritis  ||| S:746 E:756 ||| NN
and  ||| S:756 E:760 ||| CC
that  ||| S:760 E:765 ||| WDT
have  ||| S:765 E:770 ||| VBP
had  ||| S:770 E:774 ||| VBN
lichen  ||| S:774 E:781 ||| JJ
planus  ||| S:781 E:788 ||| JJ
lesions  ||| S:788 E:796 ||| NNS
for  ||| S:796 E:800 ||| IN
approximately  ||| S:800 E:814 ||| RB
25  ||| S:814 E:817 ||| CD
years ||| S:817 E:822 ||| NNS
.  ||| S:822 E:824 ||| .
Only  ||| S:824 E:829 ||| RB
recently ||| S:829 E:837 ||| RB
,  ||| S:837 E:839 ||| ,
she  ||| S:839 E:843 ||| PRP
had  ||| S:843 E:847 ||| VBD
been  ||| S:847 E:852 ||| VBN
received  ||| S:852 E:861 ||| VBN
immunosuppressive  ||| S:861 E:879 ||| JJ
therapy  ||| S:879 E:887 ||| NN
( ||| S:887 E:888 ||| -LRB-
Etanercept  ||| S:888 E:899 ||| NNP
and  ||| S:899 E:903 ||| CC
Methotrexate ||| S:903 E:915 ||| NNP
) ||| S:915 E:916 ||| -RRB-
.  ||| S:916 E:918 ||| .
Further  ||| S:918 E:926 ||| RBR
on ||| S:926 E:928 ||| IN
,  ||| S:928 E:930 ||| ,
the  ||| S:930 E:934 ||| DT
lichen  ||| S:934 E:941 ||| JJ
planus  ||| S:941 E:948 ||| NNS
flared  ||| S:948 E:955 ||| VBN
up  ||| S:955 E:958 ||| RP
with  ||| S:958 E:963 ||| IN
a  ||| S:963 E:965 ||| DT
secondary  ||| S:965 E:975 ||| JJ
infection  ||| S:975 E:985 ||| NN
determined  ||| S:985 E:996 ||| VBN
by  ||| S:996 E:999 ||| IN
a  ||| S:999 E:1001 ||| DT
Methicillin-sensitive  ||| S:1001 E:1023 ||| JJ
Staphylococcus  ||| S:1023 E:1038 ||| JJ
aureus ||| S:1038 E:1044 ||| NN
.  ||| S:1044 E:1046 ||| .
Uncommon  ||| S:1046 E:1055 ||| JJ
myocardial  ||| S:1055 E:1066 ||| JJ
complications  ||| S:1066 E:1080 ||| NNS
were  ||| S:1080 E:1085 ||| VBD
also  ||| S:1085 E:1090 ||| RB
characteristic  ||| S:1090 E:1105 ||| JJ
of  ||| S:1105 E:1108 ||| IN
this  ||| S:1108 E:1113 ||| DT
case ||| S:1113 E:1117 ||| NN
.  ||| S:1117 E:1119 ||| .
While  ||| S:1119 E:1125 ||| IN
a  ||| S:1125 E:1127 ||| DT
case  ||| S:1127 E:1132 ||| NN
report  ||| S:1132 E:1139 ||| NN
described  ||| S:1139 E:1149 ||| VBD
already  ||| S:1149 E:1157 ||| RB
the  ||| S:1157 E:1161 ||| DT
appearance  ||| S:1161 E:1172 ||| NN
of  ||| S:1172 E:1175 ||| IN
lichen  ||| S:1175 E:1182 ||| JJ
planus  ||| S:1182 E:1189 ||| NNS
following  ||| S:1189 E:1199 ||| VBG
Etanercept  ||| S:1199 E:1210 ||| JJ
therapy  ||| S:1210 E:1218 ||| NN
( ||| S:1218 E:1219 ||| -LRB-
Battistella  ||| S:1219 E:1231 ||| NNP
M  ||| S:1231 E:1233 ||| NNP
et  ||| S:1233 E:1236 ||| NNP
al. ||| S:1236 E:1239 ||| NNP
,  ||| S:1239 E:1241 ||| ,
2008 ||| S:1241 E:1245 ||| CD
) ||| S:1245 E:1246 ||| -RRB-
,  ||| S:1246 E:1248 ||| ,
the  ||| S:1248 E:1252 ||| DT
possibility  ||| S:1252 E:1264 ||| NN
that  ||| S:1264 E:1269 ||| IN
the  ||| S:1269 E:1273 ||| DT
lesion  ||| S:1273 E:1280 ||| NN
could  ||| S:1280 E:1286 ||| MD
become  ||| S:1286 E:1293 ||| VB
secondary  ||| S:1293 E:1303 ||| JJ
complicated  ||| S:1303 E:1315 ||| JJ
following  ||| S:1315 E:1325 ||| VBG
this  ||| S:1325 E:1330 ||| DT
therapy  ||| S:1330 E:1338 ||| NN
was  ||| S:1338 E:1342 ||| VBD
never  ||| S:1342 E:1348 ||| RB
reported  ||| S:1348 E:1357 ||| VBD
before ||| S:1357 E:1363 ||| RB
,  ||| S:1363 E:1365 ||| ,
according  ||| S:1365 E:1375 ||| VBG
to  ||| S:1375 E:1378 ||| TO
our  ||| S:1378 E:1382 ||| PRP$
knowledge ||| S:1382 E:1391 ||| NN
.  ||| S:1391 E:1393 ||| .
Additionally ||| S:1393 E:1405 ||| RB
,  ||| S:1405 E:1407 ||| ,
we  ||| S:1407 E:1410 ||| PRP
describe  ||| S:1410 E:1419 ||| VBP
in  ||| S:1419 E:1422 ||| IN
this  ||| S:1422 E:1427 ||| DT
case  ||| S:1427 E:1432 ||| NN
the  ||| S:1432 E:1436 ||| DT
interplay  ||| S:1436 E:1446 ||| NN
between  ||| S:1446 E:1454 ||| IN
Etanercept  ||| S:1454 E:1465 ||| NNP
therapy  ||| S:1465 E:1473 ||| NN
and  ||| S:1473 E:1477 ||| CC
hypertrophic  ||| S:1477 E:1490 ||| JJ
cardiomyopathy ||| S:1490 E:1504 ||| NN
.  ||| S:1504 E:1506 ||| .
Our  ||| S:1506 E:1510 ||| PRP$
case  ||| S:1510 E:1515 ||| NN
is  ||| S:1515 E:1518 ||| VBZ
not  ||| S:1518 E:1522 ||| RB
a  ||| S:1522 E:1524 ||| DT
lichen  ||| S:1524 E:1531 ||| JJ
planus  ||| S:1531 E:1538 ||| JJ
induced  ||| S:1538 E:1546 ||| NN
by  ||| S:1546 E:1549 ||| IN
Etanercept ||| S:1549 E:1559 ||| NNP
,  ||| S:1559 E:1561 ||| ,
but  ||| S:1561 E:1565 ||| CC
it  ||| S:1565 E:1568 ||| PRP
is  ||| S:1568 E:1571 ||| VBZ
aggravated  ||| S:1571 E:1582 ||| VBN
and  ||| S:1582 E:1586 ||| CC
secondary  ||| S:1586 E:1596 ||| JJ
infected  ||| S:1596 E:1605 ||| NN
with  ||| S:1605 E:1610 ||| IN
Methicillin-sensitive  ||| S:1610 E:1632 ||| NNP
Staphylococcus  ||| S:1632 E:1647 ||| NNP
during  ||| S:1647 E:1654 ||| IN
the  ||| S:1654 E:1658 ||| DT
therapy ||| S:1658 E:1665 ||| NN
.  ||| S:1665 E:1667 ||| .
The  ||| S:1667 E:1671 ||| DT
additional  ||| S:1671 E:1682 ||| JJ
cardiac  ||| S:1682 E:1690 ||| JJ
complication  ||| S:1690 E:1703 ||| NN
( ||| S:1703 E:1704 ||| -LRB-
hypertrophic  ||| S:1704 E:1717 ||| FW
cardiomyopathy ||| S:1717 E:1731 ||| FW
)  ||| S:1731 E:1733 ||| -RRB-
may  ||| S:1733 E:1737 ||| MD
represent  ||| S:1737 E:1747 ||| VB
solely  ||| S:1747 E:1754 ||| RB
an  ||| S:1754 E:1757 ||| DT
evolutive  ||| S:1757 E:1767 ||| JJ
sign  ||| S:1767 E:1772 ||| NN
of  ||| S:1772 E:1775 ||| IN
rheumatoid  ||| S:1775 E:1786 ||| JJ
arthritis  ||| S:1786 E:1796 ||| NN
and  ||| S:1796 E:1800 ||| CC
therefore  ||| S:1800 E:1810 ||| RB
not  ||| S:1810 E:1814 ||| RB
influenced  ||| S:1814 E:1825 ||| VBN
by  ||| S:1825 E:1828 ||| IN
Etanercept ||| S:1828 E:1838 ||| NNP
.  ||| S:1838 E:1840 ||| .
